Genfit SA Operating Income 2011-2026 | GNFT

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Genfit SA

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	31.8 M	-82.9 M	-57.8 M	-69.5 M	-56.7 M	-	-	-	-	-	-

All numbers in EUR currency

Indicator range from annual reports

Maximum	Minimum	Average
31.8 M	-82.9 M	-47 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	-88 M	$ 8.64	8.07 %	$ 85.4 M	USA
Allakos ALLK	-196 M	-	-	$ 28.6 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	-70.8 M	-	-13.39 %	$ 1.45 M	USA
AlloVir ALVR	-46.2 M	-	4.14 %	$ 49.1 M	USA
Anavex Life Sciences Corp. AVXL	-51.4 M	$ 3.11	5.42 %	$ 265 M	USA
Applied Molecular Transport AMTI	-127 M	-	-	$ 10.1 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Brainstorm Cell Therapeutics BCLI	-9.95 M	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	-64.5 M	-	-	$ 8.42 M	USA
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	-244 M	-	-	$ 546 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Cabaletta Bio CABA	-172 M	$ 3.2	2.24 %	$ 322 M	USA
Amphastar Pharmaceuticals AMPH	140 M	$ 21.36	4.86 %	$ 998 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Clearside Biomedical CLSD	-24.8 M	-	-	$ 25.3 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	23.5 M	$ 1.47	5.0 %	$ 378 M	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	-9.95 M	$ 2.92	-	$ 4.81 M	Israel
Aquestive Therapeutics AQST	-71.1 M	$ 4.19	2.7 %	$ 448 M	USA
Arcutis Biotherapeutics ARQT	-12.2 M	$ 24.12	-0.37 %	$ 3.07 B	USA
Chimerix CMRX	-93.1 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-77.5 M	-	-	$ 401 M	USA
AIkido Pharma AIKI	-55.7 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	-287 M	$ 32.59	1.09 %	$ 2.16 B	USA
Autolus Therapeutics plc AUTL	-271 M	$ 1.47	-1.34 %	$ 391 M	Britain
Cidara Therapeutics CDTX	-176 M	-	-	$ 1.41 B	USA
CNS Pharmaceuticals CNSP	-16 M	$ 2.44	11.7 %	$ 1.08 M	USA
AVROBIO AVRO	10.2 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	1.06 B	-	-	$ 96.9 B	Britain
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
CTI BioPharma Corp. CTIC	-79.8 M	-	-	$ 1.2 B	USA
CureVac N.V. CVAC	-412 M	-	-	$ 867 M	Germany
Akari Therapeutics, Plc AKTX	-17.3 M	$ 4.25	8.35 %	$ 286 B	Britain
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA